Symbols

VYNE

VYNE·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 3

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Consecutive Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VYNE

Vyne Therapeutics Inc.

A clinical stage bio-pharmaceutical company that developing medicines for chronic pruritus and cough

Industry

Pharmaceutical

Established Date

Listing Date

01/25/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.vynetherapeutics.com

Security Type

Common stock

Office address

P.O. Box 125, Stewartsville, New Jersey 08886

Business

Introduction

VYNE Therapeutics Inc., incorporated in October 2011 as a Delaware corporation, was originally named Tigercat Pharma, Inc. The Company is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for inflammatory and immune-mediated diseases with significant unmet needs. The Company has exclusive worldwide rights to research, develop and commercialize small molecule bromine domain and extra-terminal domain (BET) inhibitors licensed from Tay Therapeutics Ltd. The company targets immune-mediated inflammatory diseases and focuses on novel BET inhibitors that are not currently being developed by other companies.

Company Financials

EPS

VYNE has released its 2025 Q2 earnings. EPS was reported at -0.13, versus the expected -0.29, beating expectations. The chart below visualizes how VYNE has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VYNE has released its 2025 Q4 earnings report, with revenue of 130.00K, reflecting a YoY change of 54.76%, and net profit of -4.84M, showing a YoY change of 59.77%. The Sankey diagram below clearly presents VYNE's revenue sources and cost distribution.